Effectiveness of Intravitreal Ranibizumab in Nonvitrectomized and Vitrectomized Eyes with Diabetic Macular Edema: A Two-Year Retrospective Analysis

Table 5

Comparison of the effect of intravitreal ranibizumab on BCVA, CMT, and TMV values in nonvitrectomized and vitrectomized eyes.

	F value	value	Partial eta^2
BCVA (logMAR)
Main effect of time	8.999	0.0004	0.257
Main effect of time-group interaction	2.319	0.108	0.082
Main effect of group	1.283	0.268	0.047
CMT (μm)
Main effect of time	9.419	<0.0001	0.266
Main effect of time-group interaction	1.963	0.127	0.070
Main effect of group	0.458	0.505	0.017
TMV (mm^3)
Main effect of time	11.420	<0.0001	0.305
Main effect of time-group interaction	0.429	0.685	0.016
Main effect of group	0.138	0.714	0.005

BCVA indicates best-corrected visual acuity; CMT, central macular thickness; TMV, total macular volume. Mixed-design ANOVA with one within-subject factor (time: 5 levels) and one between-subject factor (group: 2 levels). The main effect of time on BCVA (F(2.032, 52.827) = 8.999,  = 0.0004, partial eta² = 0.257), CMT (F(2.973, 77.295) = 9.419, , partial eta² = 0.266), and TMV (F(2.345, 60.957) = 11.420, , partial eta² = 0.305) was statistically significant. The main effect of time-group interaction and the group was not statistically significant (all values >0.05, Table 5). A post hoc pairwise comparison showed a significant improvement in BCVA values from baseline to the 18th and 24th months of treatment ( and , respectively). There was a significant reduction in CMT values from baseline to the 12th, 18^th, and 24th months of treatment (, , and , respectively). The reduction in TMV values was significant from baseline to the 6th, 12th, 18^th, and 24th months of treatment (, , , and , respectively). All other pairwise comparisons for BCVA, CMT, and TMV values were not statistically significant.